eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | retinal vein occlusion |
| Symptom | |macular edema |
| Sentences | 187 |
| PubMedID- 21744123 | Purpose: to report the formation of a lamellar macular hole (lmh) in four eyes with chronic cystoid macular edema (cme) associated with retinal vein occlusion (rvo). |
| PubMedID- 25092480 | Purpose: to report our results concerning the safety and efficacy of repeated sustained-release dexamethasone 0.7 mg implants (ozurdex, allergan, inc., irvine, ca) in patients with persistent macular edema (me) due to retinal vein occlusion (rvo) previously treated with anti- vegf injections. |
| PubMedID- 22606470 | We report our unusual experience while treating a case of hemicentral retinal vein occlusion with macular edema. |
| PubMedID- 23533707 | To evaluate the effects of pars plana vitrectomy (ppv) on recurrent macular edema due to branch retinal vein occlusion (brvo) after intravitreal injections of bevacizumab (ivb). |
| PubMedID- 21087958 | Predictors of short-term visual outcome after anti-vegf therapy of macular edema due to central retinal vein occlusion. |
| PubMedID- 21652108 | Conclusion: patients with macular edema due to retinal vein occlusions, who received a single intravitreal injection of triamcinolone acetate less than 6 months after the diagnosis, displayed both anatomical and functional improvement, whereas patients injected more than 6 weeks after the diagnosis of macular edema showed a cmt reduction but with less improvement in visual acuity. |
| PubMedID- 23433821 | We report the case of anterior chamber migration of a dexamethasone implant (ozurdex((r))) in a 54-year-old woman with macular edema due to a central retinal vein occlusion. |
| PubMedID- 20714746 | Background: we investigated whether pigment epithelium-derived factor (pedf) or vascular endothelial growth factor (vegf) influence macular edema in patients with branch retinal vein occlusion (brvo). |
| PubMedID- 23379834 | Changes of macular sensitivity and morphology after pars plana vitrectomy for macular edema with central retinal vein occlusion: a case series. |
| PubMedID- 26428221 | Purpose: current treatment paradigms for macular edema associated with retinal vein occlusions (rvo) often involve initial treatment with anti-vascular endothelial growth factor (vegf) agents, then switching to intravitreal dexamethasone implant (idi; ozurdex, allergan, parsippany, nj) for poor responders. |
| PubMedID- 19956967 | Macular microcirculation before and after vitrectomy for macular edema with branch retinal vein occlusion. |
| PubMedID- 21538003 | Vitreous inflammatory factors in macular edema with central retinal vein occlusion. |
| PubMedID- 21845032 | It may be most appropriate for motivated, phakic, or pseudophakic patients with simple branch retinal vein occlusions associated with macular edema and significant hemorrhage, who are unwilling or unable to tolerate more frequent intravitreal injections required for anti-vegf therapy, or for patients who have demonstrated intolerance or recalcitrant edema following anti-vegf therapy. |
| PubMedID- 24642474 | Conclusions: at 6 months dex implant led to a significant improvement in retinal sensitivity and visual acuity associated with a reduction of retinal thickness in patients with macular edema due to retinal vein occlusion. |
| PubMedID- 20801424 | Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion. |
| PubMedID- 22623869 | Two years prior to presentation, the patient developed superior hemiretinal vein occlusion (hrvo) with cystoid macular edema in the right eye. |
| PubMedID- 24684060 | The article presents examination results of 26 patients with macular edema (me) due to retinal vein occlusion (rvo) before and 1 month after an intravitreal injection of ranibizumab (lucentis). |
| PubMedID- 22474425 | The dexamethasone drug delivery system (dds) ozurdex, allergan, irvine, california is a biodegradable, sustained-release device approved by the us fda for the treatment of macular edema associated with retinal vein occlusion and noninfectious posterior segment uveitis. |
| PubMedID- 21978179 | Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. |
| PubMedID- 23883532 | Pars plana vitrectomy with multiple transvenous chorioretinotomies for macular edema due to retinal vein occlusion. |
| PubMedID- 24447389 | Additional sources of data included clinical study reports for ranibizumab , the dexamethasone ivt manufacturer’s submission to the national institute for health and clinical excellence (nice) for dexamethasone ivt and the evidence review group response and results of the global evaluation of implantable dexamethasone in retinal vein occlusion with macular edema (geneva) studies reported within the clinicaltrials.gov records . |
| PubMedID- 19763601 | Background: to evaluate prognostic factors of response to intravitreal bevacizumab therapy of macular edema (me) due to central retinal vein occlusion (crvo) or branch retinal vein occlusion (brvo). |
| PubMedID- 24830824 | Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. |
| PubMedID- 20653482 | Purpose: to evaluate secondary ocular hypertension after intravitreal injection of triamcinolone acetonide (ivta) with 2 mg/0.05 ml or 4 mg/0.1 ml for macular edema associated with retinal vein occlusion (rvo). |
| PubMedID- 23179231 | Intravitreal bevacizumab has been adopted as a well-established treatment modality for the treatment of macular edema associated with branch retinal vein occlusion. |
| PubMedID- 21275514 | Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in macular edema with central retinal vein occlusion. |
| PubMedID- 24875368 | Purpose: the aim of this study is to evaluate the long-term efficacy of intravitreal bevacizumab (ivb) in macular edema (me) due to branch retinal vein occlusion (brvo) in a real clinical practice setting at a tertiary referral center. |
| PubMedID- 19967679 | Purpose: aqueous levels of vascular endothelial growth factor (vegf) and interleukin-6 (il-6) are associated with the severity of macular edema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 22668201 | Intravitreal bevacizumab treatment for macular edema due to branch retinal vein occlusion in a clinical setting. |
| PubMedID- 21150231 | Purpose: my aim was to evaluate the effect of intravitreal bevacizumab and to determine the concentrations of inflammatory cytokines in patients with macular edema due to branch retinal vein occlusion (brvo), according to the site of the occlusion. |
| PubMedID- 24600201 | Background: the purpose of this study was to evaluate visual outcomes of arteriovenous sheathotomy for macular edema due to branch retinal vein occlusion (brvo). |
| PubMedID- 23160823 | The objective of this study is to evaluate functional and morphological changes of the macula after pars plana vitrectomy (ppv) for macular edema with branch retinal vein occlusion (brvo). |
| PubMedID- 23264870 | Figure 1 is a case of inferotemporal macular branch retinal vein occlusion (brvo) with macular edema. |
| PubMedID- 23006995 | Purpose: to evaluate the effects of repeated intravitreal dexamethasone implant (idi) (ozurdex(r)) in eyes with macular edema (me) due to retinal vein occlusion (rvo). |
| PubMedID- 24325604 | Aqueous flare and inflammatory factors in macular edema with central retinal vein occlusion: a case series. |
| PubMedID- 21941500 | The data presented in this case report indicate that the dexamethasone implant has an immediate effect on macular edema due to retinal vein occlusion that sets in within the first 72 h following the intravitreal implantation of the drug. |
| PubMedID- 24967199 | Aqueous levels of erythropoietin in acute retinal vein occlusion with macular edema. |
| PubMedID- 22492175 | Methods: we studied the relationship between foveal sensitivity, obtained as the "foveal threshold" by use of humphrey perimetry, and best-corrected visual acuity, converted to the logarithm of the minimum angle of resolution (logmar), for 117 eyes with epiretinal membrane (erm), 197 eyes with retinal vein occlusion associated with macular edema (rvome), and 158 eyes with central serous chorioretinopathy (csc). |
| PubMedID- 23764703 | This new technique is a promising treatment of macular edema due to central retinal vein occlusion. |
| PubMedID- 21866074 | Methods: the subjects were 44 branch retinal vein occlusion patients with macular edema and 16 controls. |
| PubMedID- 25820576 | The purpose of this study is to evaluate the long-term visual, anatomical and electrophysiological outcomes of repeated intravitreal injections of bevacizumab for macular edema due to retinal vein occlusion (rvo) and investigate any possible toxic effects on the central fovea. |
| PubMedID- 23355773 | Patients and methods: this retrospective, consecutive study examined 53 eyes of 53 patients with macular edema due to branch retinal vein occlusion in 25 patients (47.2%) and nonproliferative diabetic retinopathy in 28 patients (52.8%). |
| PubMedID- 24528934 | Purpose: to test a combination of dexamethasone intravitreal implant with macular grid laser for macular edema in patients with branch retinal vein occlusion (brvo). |
| PubMedID- 22246387 | Treatment of macular edema due to branch retinal vein occlusion with single or multiple intravitreal injections of bevacizumab. |
| PubMedID- 22301066 | Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the horizon trial. |
| PubMedID- 22080912 | Changes in visual acuity and foveal photoreceptor integrity in eyes with chronic cystoid macular edema associated with retinal vein occlusion. |
| PubMedID- 21494891 | Introduction: the ozurdex((r)) (allergan inc., irvine, ca, usa) dexamethasone drug delivery system (dds) was recently developed as a biodegradable intravitreal implant to provide sustained delivery of 700 mug of preservativefree dexamethasone to the retina and vitreous, and is approved by the united states food and drug administration (fda) for the treatment of macular edema associated with retinal vein occlusion, as well as for noninfectious posterior uveitis. |
| PubMedID- 24696869 | They offer an alternative route in the management of macular edema due to uveitis, retinal vein occlusion, diabetes and pseudophakia. |
| PubMedID- 25383828 | Results: initial ophthalmic examination showed bilateral central retinal vein occlusion with macular edema, including serous macular detachment in the left eye. |
| PubMedID- 21478810 | Conclusion: these results suggest that a rebound of macular edema in eyes with branch retinal vein occlusion was more likely to occur when the intravitreal bevacizumab therapy is initiated before the macular edema reaches the maximum level. |